This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Johnson & Johnson (JNJ) Ascends But Remains Behind Market: Some Facts to Note
by Zacks Equity Research
In the most recent trading session, Johnson & Johnson (JNJ) closed at $145.27, indicating a +0.55% shift from the previous trading day.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Can Dow Jones ETF Reverse From the Worst Losing Streak in 50 Years?
by Sanghamitra Saha
The Dow Jones ETF has recorded the longest losing streak since 1978. Can it reverse the trend in 2025?
Dow on a Record Losing Streak: Should You Buy its ETF?
by Sweta Killa
The Dow Jones has been on its worst losing streak in nearly 50 years. Should you buy its ETF for 2025?
SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study
by Zacks Equity Research
Treatment with a Sanofi-Teva-partnered experimental drug meets the primary goals in a mid-stage study for Ulcerative colitis and Crohn's disease indications.
GSK Gets CHMP Nod for Expanded Use of HIV Combo & Jemperli
by Zacks Equity Research
The CHMP recommends marketing approval to GSK's Vocabria plus JNJ's Rekambys for treating HIV-1 infection in adolescents aged 12 years and older.
FDA Gives CRL to J&J's BLA for Subcutaneous Rybrevant in NSCLC
by Zacks Equity Research
The FDA issues a complete response letter to JNJ's BLA seeking approval for the subcutaneous formulation of Rybrevant in EGFR-mutated non-small cell lung cancer.
Johnson & Johnson (JNJ) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
In the most recent trading session, Johnson & Johnson (JNJ) closed at $143.85, indicating a -1.89% shift from the previous trading day.
EMA Panel Endorses Lilly's Omvoh for Expanded Use in Crohn's Disease
by Zacks Equity Research
The CHMP's opinion is based on late-stage data, which show that LLY's Omvoh is effective in Crohn's disease patients with or without prior biologic failure.
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Johnson & Johnson (JNJ) Stock Moves -0.25%: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $149.23, marking a -0.25% move from the previous day.
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
ISRG Stock Reaches All-Time High: Strength in Uptrend to Continue?
by Indrajit Bandyopadhyay
Intuitive Surgical has maintained an uptrend so far this year on the back of robust da Vinci portfolio performance. The has stock also gained during the past month. Let's see if the trend might change.
Pharma Stock Roundup: LLY's Zepbound Success, FDA Updates for MRK, JNJ
by Kinjel Shah
LLY's Zepbound shows better weight loss than NVO's Wegovy in a study. FDA updates for MRK, RHHBY, JNJ and AZN drugs grab headlines.
The Zacks Analyst Blog Highlights Home Depot, Johnson & Johnson, Salesforce, Preformed Line and Cooper-Standard
by Zacks Equity Research
Home Depot, Johnson & Johnson, Salesforce, Preformed Line and Cooper-Standard are included in this Analyst Blog.
Top Analyst Reports for Home Depot, Johnson & Johnson & Salesforce
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), Johnson & Johnson (JNJ) and Salesforce, Inc. (CRM), as well as two micro-cap stocks, Preformed Line Products Company (PLPC) and Cooper-Standard Holdings Inc. (CPS).
Johnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
In the most recent trading session, Johnson & Johnson (JNJ) closed at $150.47, indicating a -1.24% shift from the previous trading day.
Amgen Stock Falls 12% in a Month: Should You Buy the Dip?
by Kinjel Shah
AMGN's reasonable valuation, an interesting pipeline and continued top-line growth are good enough reasons to stay invested in the stock for now.
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
J&J Seeks FDA Approval for Tremfya for Psoriasis in Kids
by Zacks Equity Research
J&J files for FDA approval of Tremfya for plaque psoriasis and psoriatic arthritis indications in pediatric patients
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
TEVA Stock Down 10% in a Month: Should You Buy the Dip?
by Kinjel Shah
Teva's reasonable valuation, an improving pipeline, and sales and profit growth potential are good enough reasons for those who own the stock to stay invested.
Merck Stock Up as Winrevair Meets Goal in Advanced PAH Study
by Zacks Equity Research
MRK's study of PAH drug Winrevair in a more advanced form of the disease shows overwhelming efficacy.